NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
STRO
Sutro Biopharma, Inc.
There isn't enough reported data to score STRO yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
STRO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
STRO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
STRO PE Valuation
STRO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
STRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect STRO's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus STRO down 258%.
STRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$25.50 | -$9.40 |
| Q2 2025 | -$24.70 | -$6.40 |
| Q1 2025 | -$29.20 | -$10.40 |
| Q4 2024 | -$29.60 | -$11.80 |
| Q3 2024 | -$16.10 | +$12.80 |
| Q2 2024 | -$18.30 | +$6.20 |
| Q1 2024 | -$18.80 | +$4.80 |
| Q4 2023 | -$17.80 | +$5.70 |
STRO lost $25.50 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over STRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over STRO on profitability, with a higher operating margin.
STRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.1M | -6.1% |
| Q2 2026 | $9.8M | -85% |
| Q1 2026 | $14.5M | -17% |
| Q4 2025 | $11.6M | -21% |
| Q3 2025 | $9.7M | +14% |
| Q2 2025 | $63.7M | +148% |
| Q1 2025 | $17.4M | +34% |
| Q4 2024 | $14.8M | -87% |
STRO's revenue has slid since its 2023 peak: $9M last quarter, down 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -241% | +259 points |
| Q2 2026 | -304% | -299 points |
| Q1 2026 | -204% | +190 points |
| Q4 2025 | -327% | +114 points |
| Q3 2025 | -500% | +297 points |
| Q2 2025 | -5.3% | +184 points |
| Q1 2025 | -394% | +41 points |
| Q4 2024 | -441% | -479 points |
STRO's operating margin was −241% last quarter, up 259 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over STRO on cash generation, producing positive trailing cash flow while its opponent burns cash.
STRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$15.7M |
| Q2 2026 | -$38.3M | +$6.4M |
| Q1 2026 | -$42.3M | +$25.6M |
| Q4 2025 | -$26.4M | +$45.3M |
| Q3 2025 | -$38.2M | +$26.3M |
| Q2 2025 | -$44.7M | -573% |
| Q1 2025 | -$67.9M | -$3.1M |
| Q4 2024 | -$71.7M | -610% |
STRO has burned cash in almost every quarter: −$129M over the past year, against −$223M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over STRO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
STRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +12.2K shares |
| 1 year | +96% | +8.1M shares |
| 3 years | +175% | +10.5M shares |
| 5 years | +260% | +12M shares |
| Available history | +622% | +14.3M shares |
STRO has 17M diluted shares, up 96% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
STRO Net Leverage
STRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
STRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 7.3 | Oversold |
STRO's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STRO PE vs Healthcare Sector
STRO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over STRO on trend strength, trading above more of its moving averages.
STRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 19% below |
| 20 week MA | $18.2 | 47% below |
| 50 week MA | $20.7 | 54% below |
| 100 week MA | $15.8 | 39% below |
| 200 week MA | $29.0 | 67% below |
STRO is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
STRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $109.8 | $220.8 | +101% |
| 2021 | $220.8 | $142.5 | -35% |
| 2022 | $142.5 | $68.7 | -52% |
| 2023 | $68.7 | $42.9 | -38% |
| 2024 | $42.9 | $18.9 | -56% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.59 | -17% |
STRO has the edge over NVO on returns for 2026, with the stronger performance.